The SPARC score: A multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer

Manuel S. Eisenberg, Stephen A. Boorjian, John C. Cheville, R. Houston Thompson, Prabin Thapa, Dharam Kaushik, Igor Frank

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose: While multiple independent clinicopathological variables are associated with the outcome of radical cystectomy for bladder cancer, limited prediction tools exist to facilitate individualized risk assessment. We developed the SPARC (Survival Prediction After Radical Cystectomy) score, a prediction model for bladder cancer specific survival after radical cystectomy. Materials and Methods: We evaluated 2,403 patients who underwent radical cystectomy without neoadjuvant therapy at our institution between 1980 and 2008 with pathological re-review of all specimens. Of these patients 1,776 with nonmetastatic urothelial carcinoma were identified for analysis. A multivariate model was developed using stepwise selection to determine variables associated with cancer specific survival. We created a scoring system based on the b coefficients of this model. Results: Median followup after radical cystectomy in patients alive at last followup was 10.5 years (IQR 7.3, 15.3), during which time 610 had died of bladder cancer. In addition to pathological tumor stage, nodal status, multifocality and lymphovascular invasion, the patient specific factors of Charlson comorbidity index, Eastern Cooperative Oncology Group (ECOG) performance status, current smoking, preoperative hydronephrosis and receipt of adjuvant chemotherapy were significantly associated with the risk of bladder cancer death. We used cumulative scores of these variables to stratify patients into risk groups with 95%, 80%, 60%, 38% and 23% 5-year cancer specific survival from the lowest to the highest risk group, respectively (p <0.0001). The concordance index of this model was 0.75. Conclusions: We present a model to individualize the estimation of cancer specific survival after radical cystectomy. Pending external validation, these data may be used for patient counseling, specifically in regard to recommendations for adjuvant therapy and surveillance frequency, as well as for clinical trial development.

Original languageEnglish (US)
Pages (from-to)2005-2010
Number of pages6
JournalJournal of Urology
Volume190
Issue number6
DOIs
StatePublished - Dec 2013

Fingerprint

Cystectomy
Urinary Bladder Neoplasms
Survival
Neoplasms
Neoadjuvant Therapy
Hydronephrosis
Adjuvant Chemotherapy
Comorbidity
Counseling
Smoking
Clinical Trials
Carcinoma

Keywords

  • Cystectomy
  • Mortality
  • Nomograms
  • Prognosis
  • Urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Eisenberg, M. S., Boorjian, S. A., Cheville, J. C., Thompson, R. H., Thapa, P., Kaushik, D., & Frank, I. (2013). The SPARC score: A multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer. Journal of Urology, 190(6), 2005-2010. https://doi.org/10.1016/j.juro.2013.06.022

The SPARC score : A multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer. / Eisenberg, Manuel S.; Boorjian, Stephen A.; Cheville, John C.; Thompson, R. Houston; Thapa, Prabin; Kaushik, Dharam; Frank, Igor.

In: Journal of Urology, Vol. 190, No. 6, 12.2013, p. 2005-2010.

Research output: Contribution to journalArticle

Eisenberg, MS, Boorjian, SA, Cheville, JC, Thompson, RH, Thapa, P, Kaushik, D & Frank, I 2013, 'The SPARC score: A multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer', Journal of Urology, vol. 190, no. 6, pp. 2005-2010. https://doi.org/10.1016/j.juro.2013.06.022
Eisenberg, Manuel S. ; Boorjian, Stephen A. ; Cheville, John C. ; Thompson, R. Houston ; Thapa, Prabin ; Kaushik, Dharam ; Frank, Igor. / The SPARC score : A multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer. In: Journal of Urology. 2013 ; Vol. 190, No. 6. pp. 2005-2010.
@article{62677fd4aeb94b60bbf045df2e2446f4,
title = "The SPARC score: A multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer",
abstract = "Purpose: While multiple independent clinicopathological variables are associated with the outcome of radical cystectomy for bladder cancer, limited prediction tools exist to facilitate individualized risk assessment. We developed the SPARC (Survival Prediction After Radical Cystectomy) score, a prediction model for bladder cancer specific survival after radical cystectomy. Materials and Methods: We evaluated 2,403 patients who underwent radical cystectomy without neoadjuvant therapy at our institution between 1980 and 2008 with pathological re-review of all specimens. Of these patients 1,776 with nonmetastatic urothelial carcinoma were identified for analysis. A multivariate model was developed using stepwise selection to determine variables associated with cancer specific survival. We created a scoring system based on the b coefficients of this model. Results: Median followup after radical cystectomy in patients alive at last followup was 10.5 years (IQR 7.3, 15.3), during which time 610 had died of bladder cancer. In addition to pathological tumor stage, nodal status, multifocality and lymphovascular invasion, the patient specific factors of Charlson comorbidity index, Eastern Cooperative Oncology Group (ECOG) performance status, current smoking, preoperative hydronephrosis and receipt of adjuvant chemotherapy were significantly associated with the risk of bladder cancer death. We used cumulative scores of these variables to stratify patients into risk groups with 95{\%}, 80{\%}, 60{\%}, 38{\%} and 23{\%} 5-year cancer specific survival from the lowest to the highest risk group, respectively (p <0.0001). The concordance index of this model was 0.75. Conclusions: We present a model to individualize the estimation of cancer specific survival after radical cystectomy. Pending external validation, these data may be used for patient counseling, specifically in regard to recommendations for adjuvant therapy and surveillance frequency, as well as for clinical trial development.",
keywords = "Cystectomy, Mortality, Nomograms, Prognosis, Urinary bladder neoplasms",
author = "Eisenberg, {Manuel S.} and Boorjian, {Stephen A.} and Cheville, {John C.} and Thompson, {R. Houston} and Prabin Thapa and Dharam Kaushik and Igor Frank",
year = "2013",
month = "12",
doi = "10.1016/j.juro.2013.06.022",
language = "English (US)",
volume = "190",
pages = "2005--2010",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - The SPARC score

T2 - A multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer

AU - Eisenberg, Manuel S.

AU - Boorjian, Stephen A.

AU - Cheville, John C.

AU - Thompson, R. Houston

AU - Thapa, Prabin

AU - Kaushik, Dharam

AU - Frank, Igor

PY - 2013/12

Y1 - 2013/12

N2 - Purpose: While multiple independent clinicopathological variables are associated with the outcome of radical cystectomy for bladder cancer, limited prediction tools exist to facilitate individualized risk assessment. We developed the SPARC (Survival Prediction After Radical Cystectomy) score, a prediction model for bladder cancer specific survival after radical cystectomy. Materials and Methods: We evaluated 2,403 patients who underwent radical cystectomy without neoadjuvant therapy at our institution between 1980 and 2008 with pathological re-review of all specimens. Of these patients 1,776 with nonmetastatic urothelial carcinoma were identified for analysis. A multivariate model was developed using stepwise selection to determine variables associated with cancer specific survival. We created a scoring system based on the b coefficients of this model. Results: Median followup after radical cystectomy in patients alive at last followup was 10.5 years (IQR 7.3, 15.3), during which time 610 had died of bladder cancer. In addition to pathological tumor stage, nodal status, multifocality and lymphovascular invasion, the patient specific factors of Charlson comorbidity index, Eastern Cooperative Oncology Group (ECOG) performance status, current smoking, preoperative hydronephrosis and receipt of adjuvant chemotherapy were significantly associated with the risk of bladder cancer death. We used cumulative scores of these variables to stratify patients into risk groups with 95%, 80%, 60%, 38% and 23% 5-year cancer specific survival from the lowest to the highest risk group, respectively (p <0.0001). The concordance index of this model was 0.75. Conclusions: We present a model to individualize the estimation of cancer specific survival after radical cystectomy. Pending external validation, these data may be used for patient counseling, specifically in regard to recommendations for adjuvant therapy and surveillance frequency, as well as for clinical trial development.

AB - Purpose: While multiple independent clinicopathological variables are associated with the outcome of radical cystectomy for bladder cancer, limited prediction tools exist to facilitate individualized risk assessment. We developed the SPARC (Survival Prediction After Radical Cystectomy) score, a prediction model for bladder cancer specific survival after radical cystectomy. Materials and Methods: We evaluated 2,403 patients who underwent radical cystectomy without neoadjuvant therapy at our institution between 1980 and 2008 with pathological re-review of all specimens. Of these patients 1,776 with nonmetastatic urothelial carcinoma were identified for analysis. A multivariate model was developed using stepwise selection to determine variables associated with cancer specific survival. We created a scoring system based on the b coefficients of this model. Results: Median followup after radical cystectomy in patients alive at last followup was 10.5 years (IQR 7.3, 15.3), during which time 610 had died of bladder cancer. In addition to pathological tumor stage, nodal status, multifocality and lymphovascular invasion, the patient specific factors of Charlson comorbidity index, Eastern Cooperative Oncology Group (ECOG) performance status, current smoking, preoperative hydronephrosis and receipt of adjuvant chemotherapy were significantly associated with the risk of bladder cancer death. We used cumulative scores of these variables to stratify patients into risk groups with 95%, 80%, 60%, 38% and 23% 5-year cancer specific survival from the lowest to the highest risk group, respectively (p <0.0001). The concordance index of this model was 0.75. Conclusions: We present a model to individualize the estimation of cancer specific survival after radical cystectomy. Pending external validation, these data may be used for patient counseling, specifically in regard to recommendations for adjuvant therapy and surveillance frequency, as well as for clinical trial development.

KW - Cystectomy

KW - Mortality

KW - Nomograms

KW - Prognosis

KW - Urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84888636623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888636623&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2013.06.022

DO - 10.1016/j.juro.2013.06.022

M3 - Article

C2 - 23770147

AN - SCOPUS:84888636623

VL - 190

SP - 2005

EP - 2010

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -